Drug intelligence / Profile preview

Flexilev

Development stage
Unknown
Lead developer
Navamedic
Modality
Small Molecules
Administration
Oral
01

Overview

Flexilev is a branded **oral levodopa + carbidopa microtablet formulation** for symptomatic treatment of idiopathic Parkinson's disease. It consists of **water-soluble dispersible minitablets containing levodopa 5 mg and carbidopa 1.25 mg** in a 4:1 ratio, designed for **individualized, frequent, small-increment dosing** to help smooth levodopa plasma exposure and reduce motor fluctuations in patients with advancing disease. Pharmacologically, levodopa serves as the dopamine precursor that is converted in the brain to dopamine, while carbidopa is a peripheral aromatic L-amino acid decarboxylase inhibitor that reduces peripheral levodopa conversion and improves central delivery. The product has been developed and commercialized by Navamedic following acquisition of Sensidose, and is used together with dedicated dose-dispensing devices such as OraFID or MyFID to support precision titration and adherence in Parkinson's care.

Brand names
Flexilev
Other names
levodopa + carbidopa microtabletslevodopa + carbidopa dispersible microtabletslevodopa + carbidopa 5 mg + 1.25 mg dispersible tablets for dose dispenser
02

Targets

DDC (Aromatic L-amino acid decarboxylase)

Beyond the preview

Go deeper on Flexilev.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flexilev.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call